Products/Services Used | Details | Operation |
---|---|---|
Peptide Synthesis> | The 9-mer RdRp829-837 peptide (LPYPDPSRI), 10-mer RdRp829-838 peptide (LPYPDPSRIL) and the four RdRp829-837 variant peptides ((LPYPNPSRI, LPYPDASRI, LPYPDVSRI, and YPYPDVSRI) (purity > 95 %) were synthesized, purified by high-performance liquid chromatography and validated by mass spectrometry from Genscript (China). | Get A Quote |
Background: Coronavirus disease 2019 (COVID-19) continues to be a major global public health challenge, with the emergence of variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Current vaccines or monoclonal antibodies may not well be protect against infection with new SARS-CoV-2 variants. Unlike antibody-based treatment, T cell-based therapies such as TCR-T cells can target epitopes that are highly conserved across different SARS-CoV-2 variants. Reportedly, T cell-based immunity alone can restrict SARS-CoV-2 replication. Methods: In this study, we identified two TCRs targeting the RNA-dependent RNA polymerase (RdRp) protein in CD8 + T cells. Functional evaluation by transducing these ... More